Drugs / Mistletoe extract

Trials 6 · a red edge is where a trial was stopped

20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT03051477 Mar 2017 → Jan 2021 neoplasm Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Completed No outcome recorded
Phase 1 NCT00049608 Jul 2002 → Aug 2011 breast cancer, colorectal cancer, lung cancer, malignant pancreatic neoplasm National Center for Complementary and Integrative Health (NCCIH) Terminated No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT02007005 Jan 2004 → Feb 2012 superficial urinary bladder carcinoma Abnoba GmbH Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00516022 Apr 2007 → Mar 2011 non-small cell lung carcinoma Rambam Health Care Campus Completed No outcome recorded
Phase 32 trials
Phase 3 NCT02106572 Apr 2015 → Mar 2026 superficial urinary bladder carcinoma Abnoba GmbH Terminated No outcome recorded
Phase 3 NCT02191540 Jan 2011 → Jan 2013 pleural neoplasm Abnoba Korea Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as mistletoe extract mistletoe extractNCT00049608
1

NCT00516022

Known as Abnoba Viscum ClinicalTrials.gov intervention name — accepted as the source's own label NCT02191540
Known as abnobaVISCUM 900 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02106572
Known as abnobaVISCUM Fraxini ClinicalTrials.gov intervention name — accepted as the source's own label NCT02007005
Known as European Mistletoe European Mistletoe (Viscum album L.) extracts (mistletoe) are commonly used for cancer treatment in Europe.” PMID 24285980 Oct 2013
Known as Helixor M ClinicalTrials.gov intervention name — accepted as the source's own label NCT03051477
Known as mistletoe “European Mistletoe (Viscum album L.) extracts (mistletoe) are commonly used for cancer treatment in Europe.” PMID 24285980 Oct 2013
Route Subcutaneous “mistletoe subcutaneously daily starting on day 8 of course 1” NCT00049608